McGill University Health Centre (MUHC) news
The McGill University Health Centre (MUHC) Emergency Department (ED) at the Montreal General Hospital are boasting performance statistics that made them one of the top performing EDs on the Island of Montreal in September.
Diabetes, a major cause of heart disease, is a growing health concern across North America. A landmark study being conducted at the McGill University Heath Centre (MUHC) will investigate strategies used to reduce the frequency of heart disease in people with type 2 diabetes.
MUHC MONTREAL CHEST INSTITUTE RESEARCHERS: Ultra-violet irradiation in ventilation systems could reduce office sickness
Sickness among millions of office workers in industrialised countries could be reduced by the use of ultraviolet radiation to kill bacteria and moulds in ventilation systems, conclude authors of a McGill University Health Centre study published in this week's issue of The Lancet.
The Montreal Children's Hospital of the McGill University Health Centre (MUHC) expands its Acute Pain Service to help alleviate the discomfort children suffer after surgery or due to some medical diseases such as sickle cell anaemia.
Over the next week, the McGill University Health Centre pays tribute to over 1000 employees who have dedicated 25-years or more of service to the MUHC.
McGill University Health Centre (MUHC) announced today the completion of a $7.2 million project to modernize its heating and cooling systems at two of its sites.
Approximately, forty percent of the world's population is at risk of malaria infection. New research from McGill University and the Research Institute of the McGill University Health Centre suggests that some individuals may be naturally resistant to this infection.
To mark the 100th anniversary of The Montreal Children's Hospital and celebrate its many achievements, a group of prominent Quebecers has launched a Declaration of Support to recognize the Hospital's excellence in pediatric health care.
The disease modifying anti-rheumatic arthritis drug (DMARD), leflunomide does not have a higher risk of liver side effects than the traditional drug, but other newer DMARDs may, according to investigators at the Research Institute of the McGill University Health Center (MUHC).